Introduction
Congenital heart defects (CHDs) are the most prevalent of all human birth defects (6-8 every 1000 live births) 1, 2 and ventricular septum defects (VSDs) are among the most common CHDs. 2 Unrepaired VSDs cause ventricular dilation leading to heart failure, pulmonary arterial hypertension, arrhythmias and ultimately decreased life expectancy. [3] [4] [5] [6] The molecular causes of VSDs are mainly unknown.
The most frequent genetic alterations associated to VSDs in humans and mice are mutations in transcription factors or master regulators of myocardium formation like Nkx2.5 and Gata4. 7 Hypertrabeculation and noncompaction of the myocardial wall (MW) are also common defects associated with CHDs. 8 These defects are closely tied during cardiac embryogenesis and associated to left 9 The etiology and pathogenesis of this disorder are largely unknown mainly because of the lack of understanding in the underlying molecular and cellular mechanisms.
In the mouse, cardiac morphogenesis begins at E6.5-E7.5 when a subset of mesodermal cells progressively migrates antero-laterally to form the cardiac crescent. 10 At $E8.0, the bilateral cardiac primordia coalesce and fuse at the embryonic midline to form a single primary heart tube.
The primitive heart consists of two layers, an inner endocardium and the outer myocardium from which trabecular and compact zones will arise.
The heart tube initiates a characteristic rightward bend, and the initial anterior-posterior polarity transforms into a right-left patterning. At E9.5, a third tissue, the epicardium, develops from splanchnic mesoderm, migrates and covers the entire myocardial surface by E11.0. [11] [12] [13] By E13.5 four chamber are formed with septa dividing atrial and ventricular chambers. [12] [13] [14] Members of the large family of T-box (Tbx) transcription factors play a crucial role during cardiac regionalization. In the developing mammalian heart, 6 of the 17 family members of Tbx genes (Tbx1, Tbx18 and Tbx20 of the Tbx1 subfamily and Tbx2, Tbx3 and Tbx5 of the Tbx2 subfamily) are expressed in a combinatorial fashion in different progenitor pools and in different compartments. 15, 16 Several Tbx mutations are associated with CHDs. For example, TBX1 and TBX5 loss of function mutations are, respectively, linked to the Di George and Holt-Oram syndromes in humans. 17, 18 Among the cAMP hydrolyzing phosphodiesterases (Pdes), Pde2A is essential for mouse development. In previous work, no Pde2A knockout newborns were found alive, 19, 20 indicating that its function cannot be substituted by other Pdes. The Pde2A gene encodes several splice forms that are translated in five variants (NM_001143848.2, NM_001008548.4, NM_001143849.2, 001243757.1, NM_001243758.1) which contribute to differential modulation and localization of cAMP signals. 21 Pde2A activity leads to changes in cAMP/PKA-dependent gene expression through three nuclear activators: cAMP response element-binding protein (CREB), cAMP responsive element modulator (CREM) and activating transcription factor 1 (ATF-1). 22 Inducible cAMP early repressors (ICER) are members of the CREM family, which are generated through an alternative promoter in the CREM gene, following a cAMP surge. ICERs function inhibiting gene transcription driven by the cognates CREB and ATF- 1. 23 In this paper, we investigated whether Pde2A plays a role during heart development. The results show that hemizygous deletion of Pde2A gene is tolerated during embryonic and postnatal life, and the heart appears to develop normally, whereas homozygous deletion of Pde2A leads to fetal death before E16 and hearts show atrial defects, incomplete formation of the interventricular septum (IVS) and an alteration of the myocardium maturation. These findings were confirmed by pharmacological inhibition of Pde2A activity in vivo. Cell proliferation, cell survival and the electrical conduction system are altered in Pde2A knockout hearts. Pharmacological inhibition of Pde2A activity in vivo produced similar results.
Expression of cardiac progenitor and neural crest markers, as well as cardiomyocyte differentiation markers are down-regulated in both embryonic and fetal Pde2A knockout hearts, whereas Tbx genes are down-regulated and Icer up-regulated only in Pde2A deficient fetal hearts. These results correlate with an increase in intracellular cAMP levels in Pde2A knockout hearts. Our data indicate that Pde2A is indispensable for the early phase of heart development controlling cardiac progenitor cell and neural crest deployment and suggest that increases in cAMP play a major role in the molecular mechanism involved in the fetal heart phenotype of Pde2A knockout mice.
Methods
Detailed Methods are available in the Supplementary material online.
Mouse husbandry and in vivo treatments

Pde2A
þ/-mice (B6; 129P2-Pde2A < tm1Dgen>/H; EM: 02366) were obtained from EMMA (UK). Timed mating was set up between Pde2A þ/-females and Pde2A þ/-males or Pde2A þ/þ C57BL/6 male mice. Hearts of the resulting E9.5-E18.5 embryos were isolated in Hanks balanced solution (Euroclone, Italy) and processed for following analyses. For in vivo treatments pregnant C57BL/6 females of 8 weeks of age were intraperitoneally injected at E4.5 or E10.5 of gestation with 0.3 mg/kg of erythro-9-(2-hydroxy-3-nonly) adenine (EHNA; Calbiochem-Merck, Germany) every 3 days until E10.5 or E13. 5 . Embryos were collected at E14. 5 . All our experimental procedures were conforming with the Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and were conducted with the approval of the Sapienza University's Animal Use for Research Ethic Committee and by the Italian Ministry of Health with protocol number DGSAF 24675-A (2013).
Histology, TUNEL and immunofluorescence
Embryos at E9.5 or embryonic hearts from E11.5 and E14.5 were fixed in 4% v/v paraformaldehyde overnight at 4 C and embedded in paraffin following standard procedures. Serial sagittal or coronal sections of whole embryos (5 lm) and hearts (6 lm), respectively, were obtained and stained with hematoxylin and eosin and with Masson's Trichrome Stain Kit (Sigma-Aldrich, MO, USA) or processed for immunofluorescence After dewaxing with toluene, antigen retrieval of the sections was performed by microwave heating in 10 mM sodium citrate buffer 3 times for 5 min prior to further analyses. TUNEL staining was performed on paraffin sections using an In situ Cell Death Detection Kit, POD (Roche, Germany) as described in the Supplementary material online. All histological analyses were performed in a blinded way in two independent laboratories.
cAMP assay
cAMP assay was performed according to manufacturer's instructions of cAMP-Glo Assay (Promega, USA).
Cardiomyocyte culture and contraction rate
Cardiomyocytes from fetal hearts were isolated and cultured as previously reported. 20 Evaluation of beat frequency (contraction rate) was recorded as previously described. 24 
qRT-PCR
Quantitative RT-PCR was carried out as described in the Supplementary material online. 
Statistical analyses
All data are expressed as mean ± SEM and analysed with one-way or two-way analysis of variance (ANOVA) with Bonferroni correction (Bonferroni post hoc Test), Student's t-test or Fisher's exact test. Differences were considered significant if *P < 0.05.
Results
Pde2A deficient embryos display morphological defects associated with heart malformations
We did not find any Pde2A -/-embryos alive after 15.5 day of gestation onwards except for one pup that was born dead (see Table 1 ) confirming that Pde2A knockout mice die in utero. 19, 20 From E13.5, it was possible to recognize Pde2A -/-embryos because of their small size, pale appearance, small liver and diffuse hemorrhages ( Figure 1A) . Many Pde2A -/-embryos displayed nuchal edema under the skin on the front of the head and in the occipital region ( Figure 1A) . Since nuchal edema is frequently associated with CHDs, 25 the presence of cardiac alterations was investigated in isolated hearts from Pde2A -/-embryos.
At E11.5, no gross morphological differences were observed in the formation of the heart tube of Pde2A þ/-or Pde2A -/-mice (see Supplementary material online, Figure S1A and B). At E14.5, the heart weight was slightly increased in Pde2A -/-(3.37 ± 0.38 mg) embryos compared to hearts of Pde2A þ/-(3.08 ± 0.25 mg) and Pde2A
(2.53 ± 0.40 mg) embryos. Moreover, Pde2A knockout hearts were enlarged and the basal side of the ventricular surcus appeared wider compared to the heterozygous and wild-type ( Figure 1B and C).
Quantitative assessment of ventricular proximo-distal and contralateral axes evidenced that the observed enlargement is mainly due to an increase of the contralateral axis in the knockouts (Pde2A Figure 1D ). No differences were observed in the length of the proximo-distal axis ( Figure 1E ). These data suggest that Pde2A gene deletion affects the heart size and leads to ventricular dilatation.
Pde2A deficiency is associated with IVS defects and thin MW
Microscopic examination revealed that knockout but not heterozygous heart sections have defective atria with smooth walls compared to the trabeculated atria walls of wild-type embryos ( Figure 1C and Supplementary material online, S1C). Moreover, a subset of mice showed atrial septal defects (see Supplementary material online, Figure  S1C and Table 2 ). The IVS of Pde2A -/-hearts at E13.5-14.5 had a normal width ( Figure 1F ), but it was not completely formed preventing the separation of the right and the left ventricles ( Figure 1C and Supplementary material online, Figure S2A , C). IVS were normally formed in Pde2A heterozygous littermates (see Supplementary material online, Figure S1C ). Pde2A þ/-110 ± 9.3 lm and Pde2A þ/þ 125 ± 6.1 lm; Figure 1C , G and ; Figure 1C , I and Table 2 ). Wall and trabecular defects were similarly observed in the right and left ventricles (see Supplementary material online, Figure S2B ). Further analyses revealed that a subset of Pde2A -/-mice showed more heart abnormalities such as overriding aorta, valves (see Supplementary material online, Figure S2A and Table 2 ) with rare occurrences of double-outlet right ventricles and outflow tract defects (data not shown and Table 2 ). Enlargement of ventricles was not associated with fibrotic tissue deposition since histological analysis did not reveal any difference in the presence of fibrotic tissue, between hearts of Pde2A þ/þ and Pde2A -/-mice, with the composition of the extracellular matrix appearing normal both in IVS and MW (see Supplementary material online, Figure S2C ). To explore whether these defects were associated to a modification of cAMP levels in fetal hearts, a measurement of the cyclic nucleotide was performed. As shown in Figure 1J , a significant increase in cAMP level was observed in the hearts of knockout embryos at E14.5, suggesting that Pde2A activity impairment is not recovered by other cAMP hydrolyzing Pdes.
Pde2A
À/À hearts show altered cell proliferation and increased cell death
Since the septum and ventricular wall defects could be due to an increase of cell death rate or a decrease of cell proliferation in these regions, both effects were analyzed. Cell proliferation was evaluated by Ki67 staining in E14.5 heart sections. A significant reduction of cell proliferation was observed in IVS, whereas a significant increase was recorded in ventricular trabeculae (VT) of Pde2A -/-hearts compared to Pde2A þ/þ and 
Each dot represents the analysis of 30 sections/embryo. Dot plots show trabeculae thickness (H) and trabeculae number (I) in E14.5 Pde2A Pde2A deficiency causes congenital heart defects in the IVS of wild-type and knockout hearts, respectively; 12.60% ± 1.31 vs. 30 .92% ± 3.55 in the VT of wild-type and knockout hearts, respectively). Further analyses revealed that cardiomyocyte proliferation was impaired and the cardiomyocyte number decreased IVS of knockout mice as revealed by staining with a pan antibody for myosin heavy chain (see Supplementary material online, Figure S3 ). Apoptotic cells were increased in the apex and in the IVS of Pde2A -/-hearts compared to Figure 2B and data not shown; 4.47% ± 0.41 vs.
7.4% ± 0.7 in the apex of wild-type and knockout hearts, respectively; 8.76% ± 1.38 vs. 18 .28% ± 1.98 in the IVS of wild-type and knockout hearts, respectively). The increase in apoptosis of hearts of knockout embryos was confirmed by western blot data analyses measuring the apoptotic marker Bak and the pro-survival marker Bcl-x L . As shown in Figure 2C , the expression of Bak was increased and Bcl-x L was decreased in the hearts of Pde2A -/-embryos compared to expression in the hearts of wild-type mice.
To further uncover which particular cell lineage was affected by the deletion of Pde2A gene, qRT-PCR was performed on specific markers for cardiomyocytes (Mef2c), fibroblasts (Vimentin), endothelial (CD31) and smooth muscle (a-SMA) cells. A substantial reduction of Mef2c and Vimentin mRNAs was observed in Pde2A À/À hearts, whereas CD31 and a-SMA markers were not affected ( Figure 2D ). Pathological ventricular remodelling could be also due to cell growth alteration. For this reason, the area of isolated cardiomyocytes was measured to assess whether cardiomyocyte growth was increased in Pde2A À/À mice. Analysis of fetal cardiomyocytes harvested from hearts at E14.5 showed no difference in cell size between Pde2A À/À and Pde2A þ/þ mice (see Supplementary material online, Figure S4 ).
Altogether these results indicate that the IVS and hypertrabeculation defects in Pde2A À/À mice are likely due to an imbalance between cardiomyocyte precursor proliferation and apoptosis.
À/À cardiomyocytes show beating alteration and increased connexin 43 (Cx43) expression Since Pde2A knockout hearts show increased cAMP levels and our previous results demonstrated that stimulation of Pde2A activity modulates contraction rate after beta adrenergic stimulation, 20 beating frequency of Pde2A À/À cardiomyocytes was measured. 24 As shown in Figure 3A , cardiomyocytes from Pde2A knockout mice spontaneously contract in vitro as the wild-types. However, the contraction rate is faster in Pde2A knockout cardiomyocytes and beating was blunted more frequently (N =3 over 9 beating syncytia) compared to cardiomyocytes obtained from wild-type and heterozygous embryos, suggesting possible arrhythmias in Pde2A knockout fetal hearts. These observations encouraged us to investigate the expression and localization of Cx43, a marker of gap junctions that modulate the electrical conduction system in the heart. An increase of Cx43 expression ( Figure 3B-D) with no evident change in localization ( Figure 3C and D) was revealed in Pde2A À/À ventricles. These data indicate that Pde2A might affect cardiomyocyte contraction rate by Cx43 modulation.
The Tbx transcription factors are down-regulated and Icer is up-regulated in
To understand the molecular basis of cardiac defects detected in Pde2A knockouts, the expression of critical genes involved in cardiac development was evaluated in hearts obtained from E14. Expression of all Tbx genes was significantly reduced in Pde2A
hearts when compared to the expression levels observed in the heart of Pde2A þ/þ littermates ( Figure 4A ). The expression of Fgf10, a direct downstream target of Tbx1, 28 was also strongly down-regulated ( Figure 4A ). 
Figure S5).
To investigate the possible mechanism by which the absence of Pde2A can regulate Tbx expression we focused on Icer, a cAMPdependent transcription repressor found to be up-regulated in cardiomyocytes treated with an inhibitor of the cAMP hydrolyzing phosphodiesterase 3 A (Pde3A). 31 We hypothesized that Icer expression could be also increased in embryonic hearts of Pde2A À/À as a consequence of increased intracellular cAMP level increase. qRT-PCR analyses revealed a significant up-regulation of Icer mRNA in Pde2A À/À hearts compared to Figure 4A ). In line with mRNAs levels, western blot analyses showed that the amount of Icer protein isoforms was increased in Pde2A À/À hearts ( Figure 4B ), whereas Tbx1 and Tbx20 expression was reduced ( Figure 4B) . These results suggest that Icer is the transcriptional repressor responsible of Tbx down-regulation in the hearts of E14.5 Pde2A knockout embryos.
Tbx expression is regulated by cAMP inducers and Pde2A activity
To test the hypothesis that Tbx gene expression depends on the intracellular level of cAMP, cardiomyocytes from E14. and Pde2A À/À hearts. Densitometry of Tbx1, Tbx20 and Icer relative to Tubulin is reported. Data are reported as dot plots of at least n = 3 hearts for each genotype. The mean value ± SEM is shown and Student's t-test was used for statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001. qRT-PCR analyses on selected Tbx genes showed that Iso stimulation induced a decrease in Tbx2, Tbx3 and Tbx5 mRNA levels ( Figure 5A ). Similar decreases were observed after Iso stimulation with the Pde2A inhibitor, whereas Pde2A inhibitor alone only down-regulated Tbx3 expression level ( Figure 5A ). To further evaluate if Tbx gene expression was also modulated by increasing cAMP production independent of b-adrenergic stimulation, experiments were performed by using forskolin (Forsk) and 3-Isobutyl-1-methylxanthine (IBMX), a cAMP inducer and a pan-Pde inhibitor, respectively. Both Forsk and Forsk þ IBMX treatments down-regulated Tbx genes. These results suggest that a robust increase in cAMP is responsible for Tbx gene down-regulation and indicates that Pde2A activity may modulate the expression of Tbx genes. Since Pde2A knockout hearts showed Icer up-regulation, mRNA levels of Pde2A and Icer were measured in treated cardiomyocyte cultures. Icer and Pde2A mRNAs were, respectively, up-regulated and down-regulated by Iso, Forsk and Forsk þ IBMX stimulations ( Figure 5A ). Altogether these results suggest a cAMP dependent down-regulation of Tbx and Pde2A genes possibly through Icer up-regulation. To further investigate the possible correlation between Pde2A and Icer, their mRNA levels were analyzed during cardiac development ( Figure 5B ). Pde2A mRNA increased during cardiac development, whereas Icer transcript was Gapdh was used as housekeeping gene for normalization. mRNA was extracted from at least n = 4 hearts for each range of development. The mean value ± SEM is shown and one-way ANOVA with Bonferroni post hoc Test was used for statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Pde2A deficiency causes congenital heart defects down-regulated, further suggesting the instauration of a negative feedback loop, similarly to what was reported for Pde3A/Icer system. 31 
Pde2A inhibition recapitulates embryonic heart defects in vivo
To test whether Pde2A activity directly induces heart defects during embryogenesis, Pde2A þ/þ pregnant females were injected with 0.03 mg/kg EHNA after blastula implantation following the timeline represented in Figure 6A . Embryos were collected at E14.5 and no evident gross phenotypes, such as nuchal edema, hemorrhages or small liver were observed ( Figure 6B) . Interestingly, histological sections of embryonic hearts after EHNA treatment showed IVS defects, hypertrabeculation and noncompaction phenotype ( Figure 6C and D-F, Table 3 ). The expression pattern of cardiac genes involved in heart development was very similar in hearts of Pde2A À/À and Pde2A-inhibited embryos. Bmp10 and
Icer were up-regulated and most of Tbx genes were down-regulated as shown by qRT-PCR and protein analyses ( Figure 6G and H). Pde2A expression was decreased by 50% c in EHNA-treated hearts, compared to the levels in untreated hearts ( Figure 6G ), confirming the results obtained in the in vitro experiments. Altogether these results demonstrate that Pde2A is a master regulator of fetal heart development modulating Tbx gene expression through the activation of the cAMPdependent repressor Icer. 3.8 Pde2A is required in the early and late phase of heart development Next, it was evaluated whether Pde2A is required in the early phase of heart development and/or it is involved in later heart remodelling and growth. EHNA was administered as shown in the timeline of Figure 7A . Mice receiving treatment I had EHNA injected from E4.5 of pregnancy until E10.5; while mice receiving treatment II had EHNA administered from E10.5 until E13. 5 . All embryos were collected at E14. 5 . If Pde2A is required in the early stage of heart development treatment I should recapitulate the phenotype of Pde2A À/À embryos; on the contrary, if Pde2A controls fetal heart growth treatment II would then recapitulate the CHDs observed in Pde2A À/À embryos. Indeed, full recapitulation of major Pde2A À/À heart defects was found to occur after treatment I in more than 60% of the embryos analyzed, whereas few defects, such as contralateral axis increase, were observed after treatment II ( Figure 7B and C). These results prompted us to investigate some specific lineage markers of cardiac progenitors of primary (c-Kit) and secondary (Islet1) heart fields and of neural crest cells (Sox9) after treatments I and II. As shown in Figure 7D , the expression of the c-Kit marker was strongly reduced after both treatments, whereas Islet1and Sox9 were decreased only after treatment I. To further investigate the role of Pde2A in early cardiogenesis, embryos were analyzed at E9. 5 . The effects of Pde2A absence on cardiac cell apoptosis and proliferation were evaluated in the hearts, outflow tract and dorsal pericardial region of E9.5 embryos ( Figure 8A) . As shown in Figure 8A -B, apoptosis was increased in cardiac Islet1-positive cells and AP2a-positive neural crest cells. Proliferation was not affected in these cell populations by the absence of PDE2 (data not shown).
Similarly to what it was observed at E14.5, c-Kit, Islet1 and Sox9 transcripts were down-regulated in the absence of Pde2A at developmental stage E9.5 ( Figure 8C) . The cardiomyocyte marker, cTnI was also downregulated at this embryonic age ( Figure 8D ). Tbx1 and 2 genes and Icer were not modulated in Pde2A À/À embryos ( Figure 8E) . Altogether, these data delineate a dual/differential role of Pde2A in early and late cardiogenesis.
Discussion
Pde2A knockout mice die by E15.5, displaying nuchal edema, anemia, diffuse hemorrhages and an extremely reduced liver size that could lead to the observed embryonic lethality. Nuchal edema is often associated with cardiac malformations 8, 17, 24, [32] [33] [34] and, in this paper, we reported that Pde2A is indispensable for heart development because Pde2A knockout embryos show severe atria and ventricular defects.
Morphological, cellular and functional defects in hearts of Pde2A knockout mice
Pde2A À/À mice die after the formation of the four heart chambers is complete. Molecular analyses indicated that early cardiac progenitors from the second heart field and neural crest are affected by Pde2A deficiency. It is noteworthy that, despite the expression of many different Pdes in the heart, 20 none of them is able to functionally compensate for Pde2A absence. Hearts of Pde2A À/À fetuses show cardiac deformities. A smooth appearance of atrial wall suggests that pectinate muscles are not formed, 35 Pde2A À/À fetuses do not completely develop the IVS, show ventricular enlargement, present ventricular hypertrabeculation, and in most of the embryos, MW noncompaction was observed. To some extent they also show atrial septal defects, overriding aorta, double-outlet right ventricle, valves and outflow tract defects. Similar abnormalities have been extensively reported in human CHDs 2, 32, 33, 36 The enlarged contralateral axis observed in Pde2A À/À hearts could be due to hypertrophy of the ventricular wall and/or to a dilated myopathy.
The ventricular wall of hearts of Pde2A À/À mice was significantly thinner than the cardiac wall of heterozygous and wild-type littermates supporting the hypothesis that the ventricles of Pde2A knockout mice are affected by dilated myopathy.
To understand the causes of the observed cardiac defects at tissue and cellular levels, proliferation, survival and growth of cardiomyocytes were investigated in Pde2A knockout mice. Proliferative and apoptotic assays displayed decreased cardiomyocyte proliferation in IVS, increased Ki67 staining in VT region and increased cellular apoptosis in the proximity of membranous septum zone. The increment of cell death in the apex, explained the establishment of a dilated myopathy with a thinner ventricular wall and an enlarged ventricular cavity. A thinner ventricular wall together with the atria defects may also lead to diminished ejection fraction, a parameter that was not possible to evaluate in fetal mice. However, through in vitro experiments, it was observed that cardiomyocyte contraction rate was slightly affected by Pde2A deletion and mutant beating cardiomyocytes tend to arrest more frequently. Moreover, Cx43 was upregulated in Pde2A knockout mouse ventricles with no evident change in cellular localization. An increase in Cx43 expression was reported to induce electrical alteration of the conduction system with cardiac arrhythmias in Duchenne patients. 37 Noteworthy, several studies reported that an increase in [38] [39] [40] The effects of Pde2A deficiency on heart structure and function may be due to the increase in cAMP production that in turn causes a significant increase in Cx43 expression.
Trabeculae formation is a landmark in the initiation of ventricular chamber maturation 41 and the trabeculae contribute to the increase of myocardial mass. 42 The thickness and increased number of trabeculae that were observed in hearts of Pde2A À/À mice, could be associated to an increase in cell proliferation. Indeed, an increase in cell proliferation was observed in trabeculae of Pde2A À/À hearts and the molecular analyses revealed that Bmp10 was up-regulated in Pde2A knockout heart. Bmp10 is a growth factor associated to proliferation of cardiomyocytes in the trabecular wall and its expression is required for trabeculae formation. 27 In mouse models of human CHDs, highest number and enlarged size of VT are associated with Bmp10 up-regulation, 8, 43 as was qRT-PCR analysis of specific markers for the heart fields, neural crest cells and cardiomyocytes in E9.5 Pde2A 6/6 and Pde2A À/À hearts. Dot plots represent relative expression levels for each analyzed gene. Gapdh was used as housekeeping gene for normalization. mRNA was analyzed on at least n = 3 hearts for each genotype. The mean value ± SEM is shown and Student's t-test was used for statistical analysis. *P< _0.05 and ***P< _0. 001. observed in Pde2A knockout hearts, supporting the correlation between Pde2A deficiency and congenital heart disease in mice.
Pde2A deficiency affects expression of Tbx cardiac specific lineage genes
We then evaluated whether Pde2A has a critical role modulating the expression of genes which regulate cardiac development. Cardiac malformations of Pde2A knockout embryos were associated to a transcript reduction of all Tbx genes and their targets in fetal stage. Several studies reported that deletion or loss of function mutations of these genes cause heart defects like those observed in Pde2A knockout mice. Tbx1 knockout mice fail to form the IVS and die at the time of birth. 44, 45 As a target gene of Tbx1, 28 Fgf10 is required for normal heart development by promoting fetal cardiomyocyte proliferation in the MW. 46 Tbx18 expression is associated with the formation of the cardiac venous pole and its presence was suggested to contribute to IVS and the left ventricle formation. Mice with complete loss of Tbx20 can develop a linear heart tube but heart looping and chamber formation do not occur; Tbx20 heterozygous mice show onset of a dilated cardiomyopathy similar to a subset of the human defects. 47, 48 Tbx2 and Tbx3 are two closely related transcription factor genes of Tbx2 subfamily. They are exclusively associated with non-chamber myocardium of the atrioventricular canal (Tbx2 and Tbx3) and outflow tract (Tbx2) during cardiac development. 47 Tbx2 acts as repressor of chamber genes in the atrioventricular region of myocardium. 49 Both of them were robustly down-regulated in Pde2A mutant mice, however e heart cavities develop in the absence of Pde2A, we might assume that the remaining Tbx2 and Tbx3 levels are sufficient for chamber formation, although they might cause the outflow tract defects observed in some Pde2A null hearts. However, we cannot exclude that these defects may be caused by other genes. For instance, other than Tbx1 and Tbx2, also loss of Mef2c function from anterior secondary heart field resulted in a spectrum of outflow tract alignment defects, ranging from overriding aorta to double-outlet right ventricles.
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Mef2c was down-regulated in Pde2A knockout hearts. Further experiments will be done to deeply understand the nature of the cellular and molecular defects of Pde2A knockout. Intriguingly, Cx43 that is normally inhibited by Tbx2, 51 was upregulated in Pde2A À/À-hearts, strengthening the hypothesis that Pde2A modulates Tbx2 gene expression. Finally, Tbx5 is associated with VSD, noncompact myocardium wall and hypertrabeculation 52 and it was strongly reduced in Pde2A knockout mice. Altogether these data suggest that Pde2A modulates the expression of several members of Tbx family and other transcription factors related to many cardiac defects found in CHDs.
4.3
Pde2A activity is responsible of fetal heart defects and correlates with Icer increase and Tbx decrease
Pde2A plays an important role degrading the cAMP pool and preventing cAMP signalling pathways in cardiomyocytes, 20 but no information was previously available on its role in cardiac development. An increase in cAMP was detected in E14.5 hearts of Pde2A knockout embryos, which can induce a constitutive activation of cAMP-dependent transcription factors and repressors. To test this hypothesis, the expression level of Icer, a cAMP-dependent repressor was evaluated in the hearts of Pde2A deficient mice. Icer mRNA was up-regulated either in fetal hearts of both Pde2A
À/À and EHNA-treated embryos. Moreover, Pde2A levels were found down-regulated in Pde2A inhibited cardiomyocytes and mice. These findings are very similar to what it has been shown for Pde3A inhibition, which activates cAMP/PKA signalling and upregulates Icer that in turn represses Pde3A gene transcription, 31 suggesting an analogous autoregulatory feedback for Pde2A. In this regard, it would be interesting to evaluate whether changes in cAMP levels affects expression of other Pdes and the cross-talk between cAMP/cGMP nucleotides.
To investigate the direct role of cAMP in Tbx expression, cells from E14.5 wild-type embryos were isolated and cultured in the presence of a selective Pde2A inhibitor and/or adenylate cyclase activators. At basal condition, Bay 60-7550 inhibitor was able to significantly reduce Tbx3 expression and cause a downward trend of other Tbx genes. However, when cAMP levels were increased by Iso, Forsk or Forsk þ IBMX stimulations Tbx2, Tbx3 and Tbx5 down-regulation was observed and notably up-regulation of Icer was detected. After Pde2A inhibition in vivo, Tbx, Icer and Pde2A transcript modulation was observed probably because a critical threshold for cAMP level was reached in these conditions. These results show for the first time that intracellular cAMP elevation in the cardiomyocytes of developing heart is fundamental for the inhibition of Tbx expression and the establishment of CHD.
Intriguingly, high affinity CRE-binding sites are present in the promoters of Tbx genes (see MatInspector software at http://www.genoma tix.de) strengthening the hypothesis that induction of Icer by the rise of cAMP might represses Tbx expression in fetal hearts.
In E9.5 hearts of wild-type mice, PDE2A mRNA is present at very low level and this might explain why Tbx1, Tbx 2 and Icer are not modulated in knockout embryos compared to their expression in the hearts of wild-type embryos. Since Tbx 1, Tbx 2 and Icer are not modulated by cAMP/PDE2 dependent pathways, in the E9.5 hearts their expression may depend by other molecular determinants for cardiac development like Bmp2 and Bmp4 29, 53, 54 and by Notch signalling. 30 
Pde2A functions in early and late heart development
We have found that Pde2A is always expressed in the heart, but its level increases during embryogenesis, indicating a potential role all over the stage of heart development. To study the exact embryonic stage at which Pde2A is required for heart development, different approaches were employed. Pde2A inhibition in vivo from E4.5 until E10.5 recapitulated the morphological abnormalities and molecular alteration of the first and second heart field observed in null embryos at E14.5, indicating that Pde2A is indispensable in the early phase of cardiogenesis. Some heart defects were observed when Pde2A was inhibited after E10.5 suggesting also a late role of Pde2A in heart development which correlates with Mef2c down-regulation in Pde2A knockout embryos. Increase in apoptosis and decrease in cardiomyocyte differentiation were observed at E9.5 in Pde2A À/À mice, which could be due to the significant decrease in specific markers of neural crest precursors and early cardiogenesis such as Sox9, c-Kit, Islet. Cardiac cell proliferation defects and alteration of Tbx gene expression were instead observed exclusively at later stages of heart development.
In conclusion, the impairment of early cardiac progenitor cells in the first and second heart fields might explain the CHDs of Pde2A deficient embryos, such as atrial and ventricular septal defects, whereas late gene expression alterations might explain the CHDs including impairment of cardiac growth, non-compaction and cardiomyocyte beating.
Study limitations and perspectives
Our observations uncover a novel and critical role of Pde2A on cardiac development and in particular on heart chamber septation and heart wall maturation. We pointed out a direct effect of Pde2A/cAMP on cardiomyocyte differentiation and survival, however we cannot exclude an indirect effect on endothelial, smooth muscle, fibroblast and blood cells; subjects of future investigation. Conditional Pde2A models are necessary to clarify the cell-specific function of Pde2A and its role in the cell-to-cell interaction. Our data support the hypothesis that increased Icer expression in Pde2A-deficient mice down-regulates Tbx gene expression, however future experiments will dissect whether Icer directly binds Tbx genes to promote their down-regulation. cAMP/PKA modulates a plethora of molecular targets that deserves further investigations; indeed intracellular Ca 2þ signalling might be affected in Pde2A
À/À cardiomyocytes, giving an explanation for the beating and connexins alteration. Expression, activity and compartmentalization of other Pde families in Pde2A knockout hearts needs also to be clarified in the future work. Furthermore, our study might give new insights to the recent debate on the role of Pde2A in cardiac hypertrophy and heart failure. 55, 56 No CHDs associated to Pde2A mutations in humans have been reported up to date. Since defects of atrial and ventricular septation are the most common type of CHDs, it will be interesting to determine how frequently mutations in Pde2A gene are associated with CHDs in humans. In mice only the complete ablation of Pde2A is critical for heart embryonic development, however this does not rule out the possibility that differential dosage/activity of Pde2A plays a role in development of the human heart by decreasing TBX1 dosage 57 or that other somatic mutations negatively synergize with hypomorphic Pde2A mutations.
